Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Omeros Corporation (OMER)

6.63   0.09 (1.38%) 08-18 06:59
Open: 6.54 Pre. Close: 6.54
High: 7.2 Low: 6.37
Volume: 971,626 Market Cap: 443(M)
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.22 - 7.26 7.26 - 7.31
Low: 6.26 - 6.32 6.32 - 6.37
Close: 6.54 - 6.63 6.63 - 6.71

Technical analysis

as of: 2022-08-17 4:25:38 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.05     One year: 10.57
Support: Support1: 5.2    Support2: 3.63
Resistance: Resistance1: 7.75    Resistance2: 9.05
Pivot: 6.08
Moving Average: MA(5): 6.84     MA(20): 5.54
MA(100): 3.93     MA(250): 6.51
MACD: MACD(12,26): 0.8     Signal(9): 0.7
Stochastic oscillator: %K(14,3): 71.4     %D(3): 76.7
RSI: RSI(14): 62.8
52-week: High: 16.56  Low: 1.86
Average Vol(K): 3-Month: 1,503 (K)  10-Days: 801 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ OMER ] has closed below upper band by 36.4%. Bollinger Bands are 115.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Headline News

Wed, 17 Aug 2022
Back-To-School Night to host biggest event yet - The Arenac County Independent

Wed, 17 Aug 2022
Omeros (OMER) Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab - StreetInsider.com

Tue, 16 Aug 2022
Larry Lee, 77, of Omer - upnorthvoice.com - Up North Voice

Tue, 16 Aug 2022
Mae MacDonald, 84, of Omer - upnorthvoice.com - Up North Voice

Tue, 16 Aug 2022
Omeros (OMER) Stock: Managing An Investment After A Winning Trade - Seeking Alpha

Wed, 10 Aug 2022
Ergin Ataman slams Omer Faruk Yurtseven and his agent Keith Glass - Eurohoops

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 63 (M)
Shares Float 60 (M)
% Held by Insiders 4 (%)
% Held by Institutions 46.4 (%)
Shares Short 12,130 (K)
Shares Short P.Month 13,290 (K)

Stock Financials

EPS -2
EPS Est Next Qtl -0.32
EPS Est This Year -1.3
EPS Est Next Year -0.7
Book Value (p.s.) -4.2
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -38.5
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.6
Qtrly Earnings Growth 0
Operating Cash Flow -85 (M)
Levered Free Cash Flow -142 (M)

Stock Valuations

PE Ratio -3.34
PEG Ratio -0.1
Price to Book value -1.58
Price to Sales 0
Price to Cash Flow -4.9

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.